{"id":"0c9b42056781","type":"article","url":"https://hartvaat.nl/2025/12/22/sefaxersen-bij-iga-nefropathie-fase-2-trial-van-complementfactor-b-remming/","title":"Sefaxersen bij IgA-nefropathie: fase 2-trial van complementfactor B-remming","title_en":"A single-arm phase 2 trial of an investigational RNA therapeutic to complement factor B sefaxersen for treatment of IgA nephropathy","category":"chronische nierziekte","category_label":"Nierziekte","professions":["apotheker","internist"],"tags":["abelacimab","complementremmers","iaso-dcm","iga-nefropathie","ijzersuppletie"],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(25)01007-5/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(25)01007-5/fulltext","authors":["Sean J. Barbour","Michelle A. Hladunewich","Michael L. McCaleb","Richard Robson","Terrance D. Barrett","Lixuan Yin","Ashley Frazer-Abel","Jay P. Garg","Richard Geary","Eugene Schneider","Gary T. Brice"],"significance":6,"published":"2025-12-22","source_date":"2025-12-22","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/contrastmiddel-en-nierfunctie/"],"congress":"","summary_en":"This phase 2 trial of sefaxersen, an RNA therapeutic targeting complement factor B, showed efficacy in IgA nephropathy, advancing complement-targeted therapy for this common glomerular disease.","created":"2026-07-03T10:25:40Z","updated":"2026-07-03T13:25:03Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Complementactivatie speelt een sleutelrol bij IgA-nefropathie. Deze eenarmige fase 2-trial onderzocht de werkzaamheid en veiligheid van sefaxersen, een antisense-oligonucleotide-remmer van complementfactor B, bij IgAN-patiënten.","abstract_original":"Activation of the complement system and subsequent local inflammation in the kidney plays a key role in the pathogenesis of IgA nephropathy (IgAN). Here, we investigated the efficacy and safety of sefaxersen, an antisense oligonucleotide inhibitor of complement factor B (FB), for the treatment of IgAN in a global exploratory, single arm, open-label trial (NCT04014335)."}